Silverarc Capital Management, LLC
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Silverarc Capital Management, LLC reported 57 stock positions worth $447.2 million. Its top holding was Nuvalent Class A (NUVL) at 7.0% of the portfolio, followed by Merus (MRUS, 6.4%) and Insmed (INSM, 5.7%). Compared with Q3 2024, it opened 11 new positions, sold out of 21, added to 34 and reduced 11. The biggest buy was a new position in Pliant Therapeutics (PLRX) and the biggest sale an exit from Alnylam Pharmaceuticals (ALNY).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001816307
- Portfolio Value
- $447.2M (Q4 2024)
- SEC Filing
- 0001420506-25-000497 ↗ filed Feb 14, 2025
Holdings Value
Holdings 57 stocks · $447.2M
| NUVL Nuvalent Inc. Class A | 7.00% | 400,014 | $31.3M | Add +7.7% |
| MRUS Merus NV | 6.40% | 680,845 | $28.6M | Add +7.2% |
| INSM Insmed Inc. | 5.75% | 372,230 | $25.7M | Add +7.1% |
| VRNA Verona Pharma Ltd. | 5.36% | 516,014 | $24.0M | Add +47.9% |
| AKRO Akero Therapeutics Inc. | 4.60% | 739,563 | $20.6M | Add +15.6% |
| VCYT Veracyte Inc. | 4.46% | 503,281 | $19.9M | Add +7.0% |
| ERAS Erasca Inc. | 4.23% | 7,543,901 | $18.9M | Add +8.6% |
| PLRX Pliant Therapeutics Inc. | 3.87% | 1,315,601 | $17.3M | New |
| SNDX Syndax Pharmaceuticals Inc. | 3.64% | 1,230,400 | $16.3M | Add +224.9% |
| RNAM Avidity Biosciences Inc. | 3.54% | 543,651 | $15.8M | Add +14.3% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.43% | 273,896 | $15.3M | Add +7.2% |
| ITCI Intra-Cellular Therapies Inc. | 3.34% | 179,085 | $15.0M | Add +7.2% |
| URGN Urogen Pharma Ltd. | 2.67% | 1,120,473 | $11.9M | Add +24.3% |
| CNTA Centessa Pharmaceuticals Ltd. | 2.24% | 598,952 | $10.0M | Reduce -19.6% |
| KOD Kodiak Sciences Inc. | 2.22% | 1,000,000 | $9.9M | Add +100.0% |
| PSTX Poseida Therapeutics Inc. | 2.17% | 1,012,307 | $9.7M | Reduce -72.5% |
| ORIC Oric Pharmaceuticals Inc. | 2.13% | 1,178,300 | $9.5M | Add +7.2% |
| TELA Tela Bio Inc. | 2.07% | 3,065,649 | $9.3M | Add +172.5% |
| SRRK Scholar Rock Holding Corp. | 1.77% | 183,243 | $7.9M | New |
| WVE Wave Life Sciences Ltd. | 1.68% | 608,897 | $7.5M | Reduce -3.0% |
| COGT Cogent Biosciences Inc. | 1.61% | 921,137 | $7.2M | Reduce -24.6% |
| ASND Ascendis Pharma A/S | 1.59% | 51,491 | $7.1M | Add +929.8% |
| IRON Disc Medicine Inc. | 1.56% | 110,381 | $7.0M | Add +6.3% |
| CLDX Celldex Therapeutics Inc. | 1.49% | 264,560 | $6.7M | Add +82.5% |
| ELUT Elutia Inc. | 1.49% | 1,782,271 | $6.7M | Add +8.3% |
| BDSX Biodesix Inc. | 1.48% | 4,332,281 | $6.6M | Add +21.7% |
| GOSS Gossamer Bio Inc. | 1.25% | 6,171,847 | $5.6M | Add +9.3% |
| PRAX Praxis Precision Medicines I | 1.25% | 72,516 | $5.6M | Add +8.2% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.21% | 513,369 | $5.4M | No change |
| RARE Ultragenyx Pharmaceutical Inc. | 1.17% | 124,388 | $5.2M | New |
| KALV Kalvista Pharmaceuticals Inc. | 1.16% | 612,173 | $5.2M | Add +6.5% |
| TVTX Travere Therapeutics Inc. | 1.08% | 277,365 | $4.8M | New |
| CCCC C4 Therapeutics Inc. | 0.98% | 1,221,131 | $4.4M | Add +6.4% |
| GPCR Structure Therapeutics Inc. | 0.92% | 152,395 | $4.1M | Add +116.1% |
| TARS Tarsus Pharmaceuticals Inc. | 0.82% | 65,955 | $3.7M | Add +64.9% |
| INCY Incyte Corp. | 0.76% | 49,000 | $3.4M | New |
| PCVX Vaxcyte Inc. | 0.75% | 40,788 | $3.3M | Reduce -32.6% |
| GERN Geron Corp. | 0.73% | 920,022 | $3.3M | Reduce -48.9% |
| TRVI Trevi Therapeutics Inc. | 0.68% | 734,234 | $3.0M | Add +52.1% |
| CGEN Compugen Ltd. | 0.56% | 1,624,377 | $2.5M | Add +8.2% |
| CERS Cerus Corp. | 0.55% | 1,587,228 | $2.4M | Add +6.2% |
| ABVX Abivax SA-ADR | 0.47% | 285,120 | $2.1M | Reduce -38.2% |
| UNICYCIVE THERAPEUTICS INC | 0.44% | 2,486,709 | $2.0M | Reduce -37.8% |
| VRDN Viridian Therapeutics Inc. | 0.43% | 100,000 | $1.9M | New |
| DCTH Delcath Systems Inc. | 0.42% | 155,325 | $1.9M | New |
| QURE Uniqure NV | 0.39% | 100,000 | $1.8M | New |
| MODULAR MED INC | 0.39% | 1,272,015 | $1.7M | Reduce -11.7% |
| KALA Kala Bio Inc. | 0.36% | 231,070 | $1.6M | New |
| OLMA Olema Pharmaceuticals Inc. | 0.30% | 233,281 | $1.4M | Reduce -48.7% |
| GILD Gilead Sciences Inc. | 0.21% | 10,000 | $924K | New |
| EYPT Eyepoint Inc. | 0.20% | 121,274 | $903K | Add +21.3% |
| RADX Radiopharm Theranostics Ltd. | 0.19% | 187,406 | $841K | New |
| ETNB 89BIO Inc. | 0.17% | 96,511 | $755K | Add +4.6% |
| VXRT Vaxart Inc. | 0.16% | 1,077,782 | $714K | Add +7.8% |
| KPTI Karyopharm Therapeutics Inc. | 0.09% | 595,990 | $403K | Add +6.7% |
| GUTS Fractyl Health Inc. | 0.08% | 176,922 | $364K | Add +6.2% |
| BIOA Bioage Labs Inc. | 0.05% | 39,974 | $231K | Reduce -60.0% |
Options reported separately and not counted above: AKERO THERAPEUTICS INC calls ($6.1M), SYNDAX PHARMACEUTICALS INC calls ($2.3M), NEUMORA THERAPEUTICS INC. calls ($1.6M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $4K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| RCKTW Rocket Pharmaceuticals in-27 | *W EXP 09/02/202 | 104,828 | $4K | No change |
Total filed on the 13F, all lines: $447.2M.
Portfolio Sells Q3 2024 → Q4 2024
| ALNY Alnylam Pharmaceuticals Inc. | Sold out | 0.00% | −2.22 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −1.49 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.44 |
| COGT Cogent Biosciences Inc. | Reduce -24.6% | 1.61% | −1.37 |
| ADCT Adc Therapeutics SA | Sold out | 0.00% | −1.27 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −1.12 |
| GERN Geron Corp. | Reduce -48.9% | 0.73% | −1.11 |
| LBPH Longboard Pharmaceuticals Inc. | Sold out | 0.00% | −0.93 |
| OLMA Olema Pharmaceuticals Inc. | Reduce -48.7% | 0.30% | −0.92 |
| BIIB Biogen Inc. | Sold out | 0.00% | −0.87 |
| PCVX Vaxcyte Inc. | Reduce -32.6% | 0.75% | −0.81 |
| ABVX Abivax SA-ADR | Reduce -38.2% | 0.47% | −0.73 |
| SLDB Solid Biosciences Inc. | Sold out | 0.00% | −0.72 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −0.70 |
| MERSANA THERAPEUTICS INC | Sold out | 0.00% | −0.68 |
| RLAY Relay Therapeutics Inc. | Sold out | 0.00% | −0.67 |
| ZVRA Zevra Therapeutics Inc. | Sold out | 0.00% | −0.55 |
| CATX Perspective Therapeutics Inc. | Sold out | 0.00% | −0.51 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -19.6% | 2.24% | −0.44 |
| BIOA Bioage Labs Inc. | Reduce -60.0% | 0.05% | −0.42 |
| XNCR Xencor Inc. | Sold out | 0.00% | −0.34 |
| MODULAR MED INC | Reduce -11.7% | 0.39% | −0.34 |
| EVGN Evogene Ltd. | Sold out | 0.00% | −0.21 |
| PSTX Poseida Therapeutics Inc. | Reduce -72.5% | 2.17% | −0.20 |
| MTEMQ Molecular Templates Inc. | Sold out | 0.00% | −0.20 |
| APLT Applied Therapeutics Inc. | Sold out | 0.00% | −0.19 |
| TIL Instil Bio Inc. | Sold out | 0.00% | −0.16 |
| BDTX Black Diamond Therapeutics I | Sold out | 0.00% | −0.10 |
| ALGS Aligos Therapeutics Inc. | Sold out | 0.00% | −0.05 |
| VYNE THERAPEUTICS INC | Sold out | 0.00% | −0.03 |
| UNICYCIVE THERAPEUTICS INC | Reduce -37.8% | 0.44% | +0.07 |
| WVE Wave Life Sciences Ltd. | Reduce -3.0% | 1.68% | +0.52 |
Portfolio Buys Q3 2024 → Q4 2024
| PLRX Pliant Therapeutics Inc. | New | 3.87% | +3.87 |
| VRNA Verona Pharma Ltd. | Add +47.9% | 5.36% | +3.10 |
| SNDX Syndax Pharmaceuticals Inc. | Add +224.9% | 3.64% | +1.99 |
| KOD Kodiak Sciences Inc. | Add +100.0% | 2.22% | +1.93 |
| SRRK Scholar Rock Holding Corp. | New | 1.77% | +1.77 |
| TELA Tela Bio Inc. | Add +172.5% | 2.07% | +1.43 |
| ASND Ascendis Pharma A/S | Add +929.8% | 1.59% | +1.42 |
| RARE Ultragenyx Pharmaceutical Inc. | New | 1.17% | +1.17 |
| TVTX Travere Therapeutics Inc. | New | 1.08% | +1.08 |
| VCYT Veracyte Inc. | Add +7.0% | 4.46% | +0.85 |
| INCY Incyte Corp. | New | 0.76% | +0.76 |
| ITCI Intra-Cellular Therapies Inc. | Add +7.2% | 3.34% | +0.59 |
| TARS Tarsus Pharmaceuticals Inc. | Add +64.9% | 0.82% | +0.52 |
| AKRO Akero Therapeutics Inc. | Add +15.6% | 4.60% | +0.46 |
| VRDN Viridian Therapeutics Inc. | New | 0.43% | +0.43 |
| DCTH Delcath Systems Inc. | New | 0.42% | +0.42 |
| IRON Disc Medicine Inc. | Add +6.3% | 1.56% | +0.41 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +7.2% | 3.43% | +0.41 |
| QURE Uniqure NV | New | 0.39% | +0.39 |
| CLDX Celldex Therapeutics Inc. | Add +82.5% | 1.49% | +0.38 |
| PRAX Praxis Precision Medicines I | Add +8.2% | 1.25% | +0.38 |
| KALA Kala Bio Inc. | New | 0.36% | +0.36 |
| TRVI Trevi Therapeutics Inc. | Add +52.1% | 0.68% | +0.31 |
| GPCR Structure Therapeutics Inc. | Add +116.1% | 0.92% | +0.23 |
| GILD Gilead Sciences Inc. | New | 0.21% | +0.21 |
| RADX Radiopharm Theranostics Ltd. | New | 0.19% | +0.19 |
| URGN Urogen Pharma Ltd. | Add +24.3% | 2.67% | +0.09 |
| ELUT Elutia Inc. | Add +8.3% | 1.49% | +0.08 |
| BDSX Biodesix Inc. | Add +21.7% | 1.48% | +0.05 |
| INSM Insmed Inc. | Add +7.1% | 5.75% | +0.03 |
| EYPT Eyepoint Inc. | Add +21.3% | 0.20% | +0.02 |
| ETNB 89BIO Inc. | Add +4.6% | 0.17% | +0.01 |
| GOSS Gossamer Bio Inc. | Add +9.3% | 1.25% | −0.01 |
| GUTS Fractyl Health Inc. | Add +6.2% | 0.08% | −0.01 |
| KPTI Karyopharm Therapeutics Inc. | Add +6.7% | 0.09% | −0.01 |
| VXRT Vaxart Inc. | Add +7.8% | 0.16% | −0.03 |
| ERAS Erasca Inc. | Add +8.6% | 4.23% | −0.04 |
| CERS Cerus Corp. | Add +6.2% | 0.55% | −0.04 |
| CGEN Compugen Ltd. | Add +8.2% | 0.56% | −0.06 |
| KALV Kalvista Pharmaceuticals Inc. | Add +6.5% | 1.16% | −0.34 |
| ORIC Oric Pharmaceuticals Inc. | Add +7.2% | 2.13% | −0.41 |
| CCCC C4 Therapeutics Inc. | Add +6.4% | 0.98% | −0.49 |
| MRUS Merus NV | Add +7.2% | 6.40% | −0.75 |
| RNAM Avidity Biosciences Inc. | Add +14.3% | 3.54% | −1.39 |
| NUVL Nuvalent Inc. Class A | Add +7.7% | 7.00% | −1.56 |
Options Activity Q3 2024 → Q4 2024
| AKERO THERAPEUTICS INC | call | New | 220,000 | $6.1M |
| SYNDAX PHARMACEUTICALS INC | call | New | 172,400 | $2.3M |
| NEUMORA THERAPEUTICS INC. | call | New | 147,200 | $1.6M |
| CCCC C4 Therapeutics Inc. | call | Sold out | 150,000 | $855Kbefore exit |
| CRBP Corbus Pharmaceuticals Holdi | call | Sold out | 17,800 | $367Kbefore exit |
| MERSANA THERAPEUTICS INC | call | Sold out | 168,300 | $318Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 64 | $898.5M | ASND, CELC, COGT, URGN, IMNM |
| Q1 2026 | 66 | $848.6M | KALV, DNTH, COGT, CELC, IMNM |
| Q4 2025 | 63 | $691.1M | ABVX, COGT, URGN, KALV, CELC |
| Q3 2025 | 72 | $690.7M | ABVX, RYTM, RNAM, NUVL, URGN |
| Q2 2025 | 56 | $488.6M | MRUS, AKRO, VRNA, URGN, RYTM |
| Q1 2025 | 66 | $478.6M | VRNA, MRUS, NUVL, AKRO, INSM |
| Q4 2024 | 57 | $447.2M | NUVL, MRUS, INSM, VRNA, AKRO |
| Q3 2024 | 67 | $443.7M | NUVL, MRUS, INSM, RNAM, ERAS |
| Q2 2024 | 65 | $405.1M | MRUS, NUVL, RNAM, URGN, ERAS |
| Q1 2024 | 72 | $356.6M | MRUS, SLDB, MORF, ORIC, MERSANA THERAPEUTICS INC |